Document is current
Any future updates will be listed below
-
Authors
Kawakami, Takeshi http://orcid.org/0000-0001-9385-9516
Todaka, Akiko
Oshima, Kotoe
Fushiki, Kunihiro
Hamauchi, Satoshi
Tsushima, Takahiro
Yokota, Tomoya
Onozawa, Yusuke
Yasui, Hirofumi
Yamazaki, Kentaro
- License Information
-
More Information
Article History
Received: 14 September 2022
Accepted: 12 January 2023
First Online: 20 January 2023
Declarations
:
: This study was approved by the Ethics Committee of Shizuoka Cancer Center (approval number 2933). All methods were conducted in accordance with the Declaration of Helsinki (1964 and later versions). Written informed consent was obtained from all patients.
: Not applicable.
: Takeshi Kawakami received honoraria from Taiho Pharmaceutical, Bayer Yakuhin, Takeda, Ono Pharmaceutical, Bristol-Myers Squibb, and Yakult Honsha. Akiko Todaka received honoraria from Ono Pharmaceutical, Yakult Honsha, Taiho Pharmaceutical, and Nihon Servier. Kentaro Yamazaki received honoraria from Chugai Pharma, Daiichi Sankyo, Yakult Honsha, Takeda, Bayer, Merck Serono, Taiho Pharmaceutical, Lilly, Sanofi, Ono Pharmaceutical, MSD, and Bristol-Myers Squibb. Kentaro Yamazaki received research funding from Taiho Pharmaceutical for his institution. Other authors have no conflict of interest, financial or others.
